Saturday 17 October 2026 Export ACH’s income statement to Excel — free account

Accendra Health, Inc.

In the quarter to June 2026, revenue fell 10.1%, EPS grew 89.7%, free cash flow fell 1,624.8% and total debt fell 13.1%, each against the same quarter a year earlier.

0.24 0.02 −7.69%

Follow ACH

Alert me

Market cap: $20.1M
P/E: 0.0×
Fwd P/E: −3.0×
Dividend yield: —
F-score: 2/9
Altman Z: 0.40
Beneish M: −2.92
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 9.54%

Capital & Financial Ratios $m

Market Cap 20.11

Revenue 2,647.25

Net Income (302.14)

Free Cash Flow (210.90)

Net Debt 1,710.41

Current Ratio 0.41

Debt/Equity (3.12)

P/E ratio 0.00

Fwd P/E (2.95)

P/S ratio 0.01

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (99.67%)

Next Y EPS Growth 3,201.74%

Next Y revenue growth (9.81%)

Next 5Y EPS Growth (15.15%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.04%

10-year low 10-year high

EV/Sales against its own 10 years 80.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	0.10	0.10
2022	0.12	0.12
2021	0.01	0.00 0.00 0.00 0.00
2020	0.01	0.00 0.00 0.00 0.00
2019	0.01	0.00 0.00 0.00 0.00
2018	0.86	0.26 0.26 0.26 0.08
2017	1.03	0.26 0.26 0.26 0.26
2016	1.02	0.26 0.26 0.26 0.26

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	243	28	282	8
Receivables	598	218	96	120
Inventory	1,111	68	74	73
Other	151	82	96	70
	2,103	2,021	548	271

	2023	2024	2025	Q'26
Payables	1,172	360	364	353
ST’ Debt	207	43	250	—
Other	397	295	264	272
	1,892	1,852	947	666

Compound Annual Growth %

	10y	5y	3y
Sales	(11.87%)	(20.10%)	(34.78%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	628	613	—	—	—
’25	674	682	697	709	2,762
’24	2,613	660	687	—	2,680
’23	2,523	2,563	2,592	—	2,553
’22	2,407	2,500	2,497	2,551	9,955
’21	2,327	2,489	2,502	2,467	9,785
’20	2,123	1,808	2,188	2,362	8,480

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(50)	(26)	—	—	—
’25	(35)	38	(173)	68	(102)
’24	(53)	116	27	71	161
’23	158	313	157	112	741
’22	80	90	69	87	325
’21	25	(13)	61	50	124
’20	93	57	118	71	339

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	4	(59)	—	—	—
’25	(66)	(3)	(239)	84	(225)
’24	(53)	88	(16)	30	49
’23	124	282	125	103	634
’22	69	41	43	54	207
’21	19	(25)	48	33	74
’20	88	51	104	38	280

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.08)	(1.16)	—	—	—
’25	(0.32)	(11.30)	(1.94)	(0.73)	(14.31)
’24	(0.29)	(0.42)	(0.17)	(3.84)	(4.73)
’23	(0.32)	(0.37)	(0.08)	0.23	(0.54)
’22	0.52	0.37	0.16	(0.77)	0.29
’21	0.98	0.87	0.58	0.55	2.94
’20	(0.19)	(0.91)	0.76	0.72	0.47

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	30.43	17.75	5.83	2.43	3.63	23.58	14.10	11.79	11.42	2.38	Analyst estimates 2026–2028 Powerpack
	High	41.48	37.02	22.91	8.43	31.68	49.16	49.11	23.66	28.35	15.54
People
People	Employees	7,900	8,600	17,900	15,400	18,800	17,300	22,500	22,200	23,200	6,500
	Revenue/emp, $m	1.23	1.08	0.53	0.60	0.45	0.57	0.44	0.11	0.12	0.42
Income, $m
Income, $m	Revenue	9,723	9,318	9,418	9,211	8,480	9,785	9,955	2,553	2,680	2,762
	Gross margin, %	12.21	12.58	11.37	12.25	15.10	15.46	18.35	47.68	47.77	46.68
	EBT	173	57	(427)	(29)	110	277	11	15	(330)	(102)
	EBT margin, %	1.77	0.62	(4.53)	(0.31)	1.30	2.83	0.11	0.60	(12.31)	(3.69)
	Net income	109	73	(437)	(62)	30	222	22	(41)	(363)	(1,101)
	Depreciation	55	59	542	117	93	91	229	210	488	215
Per share, $
Per share, $	Revenue	159.16	155.30	156.93	152.06	133.82	134.52	133.64	33.68	34.92	35.92
	Earnings	1.76	1.20	(7.28)	(1.03)	0.47	3.05	0.30	(0.54)	(4.73)	(14.31)
	Cash flow	3.07	0.95	1.93	2.74	5.35	1.71	4.36	9.77	2.10	(1.32)
	Capex	(0.41)	(0.83)	(1.07)	(0.86)	(0.93)	(0.68)	(1.59)	(1.41)	(1.47)	(1.60)
	Free cash flow	2.67	0.11	0.86	1.88	4.42	1.02	2.78	8.36	0.64	(2.93)
	Book value	15.71	16.92	8.64	7.63	11.24	12.90	12.69	12.19	7.64	(5.99)
	Shares, m	61	60	60	61	63	73	74	76	77	77
Valuation, ×
Valuation, ×	P/E	20.51	16.01	0.00	0.00	69.36	14.26	63.23	0.00	0.00	0.00
	P/S	0.23	0.12	0.04	0.03	0.20	0.32	0.15	0.57	0.37	0.08
	P/B	2.31	1.14	0.73	0.68	2.41	3.37	1.54	1.58	1.71	0.00
	EV/Sales	0.29	0.23	0.23	0.19	0.31	0.42	0.39	1.30	1.05	0.72
	EV/FCF	17.18	322.51	41.94	15.70	9.47	55.05	18.82	5.23	57.77	(8.81)
Cash, $m
Cash, $m	Operating cash flow	188	57	116	166	339	124	325	741	161	(102)
	Capex	(25)	(50)	(64)	(52)	(59)	(50)	(118)	(107)	(113)	(123)
	Free cash flow	163	7	52	114	280	74	207	634	49	(225)
Balance, $m
Balance, $m	Working capital	927	872	1,067	991	790	978	729	211	169	(399)
	Total debt	565	901	1,648	1,541	1,020	992	2,501	2,098	1,841	2,050
	Net debt	379	796	1,582	1,474	937	936	2,431	1,854	1,814	1,768
	Shareholders’ equity	960	1,015	518	462	712	939	946	924	586	(461)
Returns, %
Returns, %	ROA	3.92	2.35	(12.22)	(1.68)	0.86	6.45	0.50	(0.79)	(7.44)	(30.97)
	ROIC	9.32	3.08	(10.49)	2.36	7.74	12.29	2.64	3.00	(5.67)	1.31
	ROE	11.03	7.26	(56.98)	(12.72)	5.09	26.85	2.38	(4.42)	(48.02)	(1,755.61)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CAH Cardinal Health, Inc.	$58.8B	35.0×	23.3×	+5.84% (above 0%: growing)	+68.32% (above 0%: growing)	+10.87% (above 0%: growing)	4.02%	1.14%	Compare
HSIC Henry Schein, Inc.	$9.7B	25.0×	18.5×	+6.73% (above 0%: growing)	+16.90% (above 0%: growing)	+140.91% (above 0%: growing)	31.84%	4.95%	Compare
AHG Akso Health Group Sponsored ADR	$1.2B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%	Compare
FOCL FocalTherics	$154.8M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)	Compare
COSM Cosmos Health Inc.	$33.9M	— (loss-making)	25.1×	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)	Compare
ACH Accendra Health, Inc.	$20.1M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)
HKPD Cellyan Biotechnology Co., Ltd	$17.1M	—	—	—	—	−90.45% (below 0%: shrinking)	—	—	Compare
YI 111, Inc. Sponsored ADR	$16.0M	— (loss-making)	— (loss-making)	−29.61% (below 0%: shrinking)	n/m	−185.70% (below 0%: shrinking)	5.33%	(0.85%)	Compare
SNYRQ Synergy CHC Corp.	$1.3M	— (loss-making)	1.6×	−32.77% (below 0%: shrinking)	n/m	−148.51% (below 0%: shrinking)	72.29%	(10.32%)	Compare
Median of peers	$94.3M	—	20.9×	+6.73%	—	−40.53%	7.96%	(0.85%)

All 11 Medical Distribution stocks →

Accendra Health, Inc. (ACH) key facts

Concern: Accendra Health, Inc. reported a net loss of $1.1 billion, or a loss of $14.31 per share, for fiscal 2025.
Accendra Health, Inc. (ACH) is a Medical Distribution company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, ACH traded at $0.24, a market capitalization of $20.1 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.0× sales.
Return on equity was −1,755.6% and debt-to-equity -3.12.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.40 (distress zone) for fiscal 2025.